Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AGER | Q15109 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27086715 | 0.90 | OPRM1 (0.52) | OPRM1OPRD1OPRK1HTR6MAPT | |
| SCHEMBL27086718 | 0.90 | OPRM1 (0.52) | OPRM1OPRD1OPRK1HTR6MAPT | |
| SCHEMBL29937663 | 0.88 | OPRM1 (0.63) | OPRM1OPRD1OPRK1HTR6MAPT | |
| SCHEMBL23356994 | 0.78 | OPRD1 (0.65) | OPRM1OPRD1OPRK1HTR6MAPT | |
| SCHEMBL23356996 | 0.78 | OPRD1 (0.65) | OPRM1OPRD1OPRK1HTR6MAPT | |
| SCHEMBL29937618 | 0.77 | OPRD1 (0.64) | OPRM1OPRD1OPRK1MAPTSLC9A1 | |
| SCHEMBL29937488 | 0.76 | OPRD1 (0.56) | OPRM1OPRD1OPRK1HTR6MAPT | |
| SCHEMBL31411468 | 0.75 | SLC9A1 (0.42) | OPRM1HTR6MAPTSLC9A1MEN1 | |
| SCHEMBL27086851 | 0.74 | OPRM1 (0.51) | OPRM1OPRD1OPRK1HTR6MAPT | |
| SCHEMBL27086855 | 0.74 | OPRM1 (0.51) | OPRM1OPRD1OPRK1HTR6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168648-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. | 2024-03-21 | — | — | US | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
| US-12168648-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
| US-11634396-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | OPRM1 1/4885OPRD1 4/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.